TMDX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
189.9M
+9.2%
173.9M
+8.2%
160.8M
+11.8%
143.8M
-8.6%
157.4M
Cost of Revenue
76.8M
+5.5%
72.8M
+8.1%
67.3M
+13.7%
59.2M
-2.5%
60.8M
Gross Profit
113.2M
+11.9%
101.2M
+8.3%
93.4M
+10.5%
84.6M
-12.4%
96.6M
Operating Expenses
89.5M
+1.8%
87.9M
+21.8%
72.1M
+17.7%
61.3M
+2.1%
60.0M
R&D
31.6M
+27.1%
24.9M
+20.2%
20.7M
+35.7%
15.3M
-4.2%
15.9M
SG&A
57.8M
-8.2%
63.0M
+22.4%
51.4M
+11.8%
46.0M
+4.4%
44.1M
Operating Income
23.7M
+78.5%
13.3M
-37.5%
21.3M
-8.7%
23.3M
-36.3%
36.6M
EBITDA
34.0M
+35.0%
25.2M
-12.5%
28.7M
-4.7%
30.1M
-30.4%
43.3M
Net Income
14.7M
+100.7%
7.3M
-93.1%
105.4M
+333.3%
24.3M
-30.3%
34.9M
EPS (Basic)
$0.42
+100.0%
$0.21
-93.2%
$3.08
+333.8%
$0.71
-31.1%
$1.03
EPS (Diluted)
$0.41
+105.0%
$0.20
-92.2%
$2.57
+289.4%
$0.66
-28.3%
$0.92
Shares (Diluted)
40.7M
+12.5%
36.2M
-11.6%
40.9M
+0.5%
40.7M
+0.5%
40.6M
TransMedics (TMDX) โ€” Financials